BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37005157)

  • 21. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
    Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
    Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.
    Iguchi T; Shirabe K; Aishima S; Wang H; Fujita N; Ninomiya M; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Oda Y; Maehara Y
    Transplantation; 2015 Jun; 99(6):1236-42. PubMed ID: 25427164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of Screening for Esophagogastric Varices in Naïve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation.
    Kawakami T; Hiraoka A; Michitaka K; Ninomiya T; Hirooka M; Hiasa Y
    Dig Surg; 2017; 34(5):429-435. PubMed ID: 28196353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease.
    Tobari M; Hashimoto E; Taniai M; Nishino T; Tokushige K
    Clin J Gastroenterol; 2020 Dec; 13(6):1289-1296. PubMed ID: 32880022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Des-gamma-carboxy Prothrombin for Diagnosis of Adult Primary Cancer in Liver.
    Li Y; Chen J
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):972-976. PubMed ID: 31564273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma.
    Yang K; Lee TB; Choi BH; Park YM; Ryu JH; Joo DJ; Chu CW
    Transplant Proc; 2016 Dec; 48(10):3317-3322. PubMed ID: 27931576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
    Hiraoka A; Kumada T; Kariyama K; Toyoda H; Yasuda S; Tsuji K; Hatanaka T; Kakizaki S; Naganuma A; Ishikawa T; Tada T; Takaguchi K; Itobayashi E; Shimada N; Shibata H; Tanaka T; Tsutsui A; Nagano T; Imai M; Nakamura S; Nouso K
    Oncology; 2022; 100(2):65-73. PubMed ID: 34844247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
    Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.
    Hakamada K; Kimura N; Miura T; Morohashi H; Ishido K; Nara M; Toyoki Y; Narumi S; Sasaki M
    World J Gastroenterol; 2008 Mar; 14(9):1370-7. PubMed ID: 18322950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
    Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
    Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
    Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
    Arai T; Kobayashi A; Ohya A; Takahashi M; Yokoyama T; Shimizu A; Motoyama H; Furusawa N; Notake T; Kitagawa N; Sakai H; Imamura H; Kadoya M; Miyagawa S
    Int J Clin Oncol; 2014 Oct; 19(5):871-9. PubMed ID: 24218280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.